Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spirogen Ltd.

Division of AstraZeneca PLC
www.spirogen.com

Latest From Spirogen Ltd.

Antibody-Drug Conjugates Attract Hefty Funding To ADC Therapeutics

Swiss oncology company ADC Therapeutics, which has just added another $200m to its coffers, is developing a new class of antibody-drug conjugates that may be less visible to DNA repair mechanisms and therefore less susceptible to the development of resistance than other anticancers.

Financing Cancer

Deal Watch: NASH In The Hot Seat

Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.

BioPharmaceutical Deals

Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate

Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.

BioPharmaceutical Deals

MedImmune Leverages Spirogen Tech In ADC Collaboration With Tanabe

MedImmune LLC is combining the second-generation pyrollobenzodiazepine (PBD) warheads it picked up in a 2013 buyout of Spirogen Ltd. with Tanabe Research Laboratories USA Inc.'s antibodies in a collaboration to develop mono-specific and bi-specific antibody-drug conjugates (ADCs) against a set of cancer targets.

Cancer Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Chris Martin, MD, CEO
    Tuula Moilanen, CFO
    Philip Howard, PhD, CSO
  • Contact Info
  • Spirogen Ltd.
    Phone: (44) 207 278 0555
    QMB Innovation Centre
    42 New Rd.
    London, E1 2AX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register